Drug intelligence / Profile preview

l-ornithine l-aspartate (Miotic Pharmaceuticals)

Development stage
Unknown
Lead developer
Merz Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

HEPAHENZ is a nutraceutical liver support formulation developed by Miotic Pharmaceuticals, containing l-ornithine l-aspartate (LOLA) as its active ingredient. LOLA is a stable salt of the natural amino acids ornithine and aspartic acid, which plays a crucial role in the detoxification of ammonia in the liver and brain. The mechanism of action involves the stimulation of the urea cycle, where ornithine serves as a substrate for ornithine carbamoyltransferase and carbamoyl-phosphate synthase, and the activation of glutamine synthesis, where aspartate is utilized by glutamine synthetase. By facilitating the conversion of toxic ammonia into urea and glutamine, HEPAHENZ helps manage hyperammonemia and its complications, such as hepatic encephalopathy, in patients with chronic liver diseases like cirrhosis and fatty liver.

Brand names
HEPAHENZ
Other names
L-ornithine L-aspartateLOLAliver support formula
02

Targets

OTC (Ornithine carbamoyltransferase)CPS1 (Carbamoyl phosphate synthetase I)GLUL (Glutamine synthetase)

Beyond the preview

Go deeper on l-ornithine l-aspartate (Miotic Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-ornithine l-aspartate (Miotic Pharmaceuticals).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call